Management of immune checkpoint inhibitor-related dermatologic adverse events

Thorac Cancer. 2020 Feb;11(2):488-492. doi: 10.1111/1759-7714.13275. Epub 2019 Dec 9.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic toxicities including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms are rare. In this review, we summarize guidelines of management of immunotherapy-related toxicities, case reports, and proposed treatment recommendation.

Keywords: Dermatologic toxicities; immune checkpoint inhibitor (ICI); immune-related adverse events (IrAEs).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug-Related Side Effects and Adverse Reactions / diagnosis
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / therapy*
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Practice Guidelines as Topic / standards*
  • Prognosis
  • Skin Diseases / diagnosis
  • Skin Diseases / etiology
  • Skin Diseases / therapy*

Substances

  • Immune Checkpoint Inhibitors